Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
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
rUZanaM29W2DvUj8
